EUCTR2009-016806-18-DE进行中（未招募）不适用
Multizentrische, randomisierte Phase II-Studie zur Therapie des lokal fortgeschrittenen oder metastasierten NSCLC im Stadium IV UICC 7 mit zwei unterschiedlichen Regimen von Cisplatin / Carboplatin und Docetaxel in Kombination mit Cetuximab - TAX-ERB2
Klinik Löwenstein gGmbH0 个研究点开始时间: 2010年9月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- histologically or cytologically confirmed NSCLC stadium IV UICC 7
- •- life expectance more than 3 month
- •- ECOG performance status 0 or 1
- •- positiv EGFR status (IHC score =200)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 180
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 180
排除标准
- •- systemic chemotherapy within the last 6 months before screening
- •- radiotherapy within the last 28 days before screening
- •- known CNS-metastasis
- •- any prior or existing malignancies except for basal squamous cell skin cancer and adequately treated carcinoma in situ of the cervix
研究者
相似试验
进行中（未招募）
不适用
Multizentrische randomisierte Phase II Studie zur Therapie des lokal fortgeschrittenen oder metastasierten NSCLC (Stadium IIIB/IV) mit Cisplatin/Docetaxel oder Oxaliplatin/DocetaxelA multicenter randomized phase II trial for the therapy of locally advanced or metastatic NSCLC (stage IIIB/IV) with cisplatin/docetaxel or oxaliplatin/docetaxelEUCTR2008-002197-35-DEKrankenhaus Nordwest GmbH88
已完成
2 期
A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk myelodysplastic syndromeMDS10024324myelodysplastic syndromeNL-OMON47453Vrije Universiteit Medisch Centrum200
进行中（未招募）
1 期
A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk myelodysplastic syndrome.myelodysplastic syndromeEUCTR2008-002195-10-NLHOVON Foundation170
尚未招募
2 期
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged >= 66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT-older AML/high-risk MDS patientsmyelodysplastic syndromes10024324Acute myeloid leukemiaNL-OMON53140HOVO70
进行中（未招募）
1 期
A randomized study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy. ,EUCTR2018-000047-31-NLHOVON Foundation140